Signal active
Investment Firm
Overview
Nestlé Health Science began operations on January 1, 2011. As a wholly-owned subsidiary of Nestlé, with global headquarters in Vevey, Switzerland, Nestlé Health Science has a distinct role to play in the Nestlé’s transformation into the world’s recognised leader in Nutrition, Health and Wellness. At Nestlé Health Science, their specific quest is to become the global leader in science-based personalised nutritional solutions.
Nestlé Health Science has been established to pioneer science-based nutritional solutions in order to deliver improved personalised healthcare for medical conditions. In the longer term, the company aims to use nutritional solutions to change the healthcare paradigm and deliver affordable and effective health benefits which are also safe and sustainable.
The company intends to use Nestlé's existing HealthCare Nutrition business to build a leading health science nutrition organisation within two years. It aims to develop a product portfolio and pipeline within five years and establish market leadership, meeting its vision, within a decade from start-up. The company has access to external scientific and technological know-how through Nestlés innovation network as well as a number of venture capital funds in which the group has interests.
Highlights
2011
Insurance
10001+
15
7
4
Late Stage Venture, Private Equity
N/A
Location
Vevey, Vaud, Switzerland, Europe
Contact Information
Social
Profile Resume
Nestlé Health Science, established in 2011 and headquartered in Switzerland, Europe., specializes in Late Stage Venture, Private Equity investments across Biotechnology, Health Care, Biopharma, Therapeutics, Life Science, Software, E-Commerce, Marketplace, Retail, Sports. The organization boasts a portfolio of 15 investments, with an average round size of $69.8M and 4 successful exits. Their recent investments include Seres Therapeutics, ENTEROME, Seventure Partners, Omnes Capital, Lundbeckfonden Ventures. The highest investment round they participated in was $32.5B. Among their most notable exits are Seres Therapeutics and ENTEROME. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
15
0
7
4
Investments
15
Annouced Date | Organization Name | Industry | Money Raised |
---|---|---|---|
Jun 25, 2020 | ENTEROME | Biotechnology | 51.9M |
Jul 13, 2021 | ProciseDx | Health Care | 13.0M |
Dec 23, 2022 | - | - | null |
Jan 17, 2024 | Timeline | Biotechnology | 64.8M |
Exits
4
Funding Timeline
15
0
0
Funding Rounds
15
Nestlé Health Science has raised 15 rounds. Their latest funding was raised on Jan 17, 2024 from a Series D - Timeline round.
Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
---|---|---|---|---|
Jun 25, 2020 | Series E - ENTEROME | - | 51.9M | - |
Jul 13, 2021 | Convertible Note - ProciseDx | - | 13.0M | - |
Dec 23, 2022 | Private Equity Round - Ruipeng Pet Healthcare | - | 0 | - |
Jan 17, 2024 | Series D - Timeline | - | 64.8M | - |
Investors
0
There is no funding round available on this profile
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
Annouced Date | Fund Name | Money Raised |
---|---|---|
May 10, 2013 | OTPPLESS | 1.0M |
May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
News
Jun 25, 2024
PRNewswire - Nestlé Health Science Launches Comprehensive GLP-1Nutrition Support Platform
News
Jun 06, 2024
PRNewswire - Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023
News
Mar 28, 2024
Endpoints News - Nestlé Health Science plots next steps for C. diff drug Vowst after robust uptake
News
Feb 14, 2024
Food Business News - Nestle Health Science challenge award winners chosen
Funding Round
Jan 17, 2024
Timeline raised $64783848 on 2024-01-17 in Series D
Funding Round
Dec 23, 2022
Ruipeng Pet Healthcare raised an undisclosed amount on 2022-12-23 in Private Equity Round